Extended-Release Hydrocodone: The Devil in Disguise or Just Misunderstood?

Authors

Anne Schweighardt, St. John Fisher UniversityFollow
Katherine Juba, St. John Fisher UniversityFollow

Document Type

Article

Publication Date

10-2014

Keywords

fsc2015

Abstract

Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.

DOI

10.1177/1060028014543174

Comments

The final published version of this article is available through SAGE Journals: http://dx.doi.org/10.1177/1060028014543174

Publication Information

Schweighardt, Anne and Juba, Katherine (2014). "Extended-Release Hydrocodone: The Devil in Disguise or Just Misunderstood?." Annals of Pharmacotherapy 48.10, 1362-1365.

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.